Cargando…
Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
BACKGROUND: We evaluated the efficacy of intravitreal bevacizumab on diabetic macular edema with subfoveal and perifoveal hard exudates. MATERIALS AND METHODS: Eleven eyes (11 patients) exhibiting diabetic macular edema with subfoveal and perifoveal hard exudates were included in this prospective, n...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136986/ https://www.ncbi.nlm.nih.gov/pubmed/25143708 http://dx.doi.org/10.2147/OPTH.S66405 |
_version_ | 1782331060531494912 |
---|---|
author | Jeon, Sohee Lee, Won Ki |
author_facet | Jeon, Sohee Lee, Won Ki |
author_sort | Jeon, Sohee |
collection | PubMed |
description | BACKGROUND: We evaluated the efficacy of intravitreal bevacizumab on diabetic macular edema with subfoveal and perifoveal hard exudates. MATERIALS AND METHODS: Eleven eyes (11 patients) exhibiting diabetic macular edema with subfoveal and perifoveal hard exudates were included in this prospective, nonrandomized interventional pilot study. All patients were treated with monthly scheduled intravitreal bevacizumab injections for 6 months. Changes in the Early Treatment Diabetic Retinopathy Study best corrected visual acuity, amount of hard exudates on fundus photography, and macular edema detected by central subfield thickness on spectral domain optical coherence tomography after six serial injections, were assessed. The amount of hard exudates at each visit was evaluated as pixels in fundus photography, using an Adobe Photoshop program. RESULTS: Ten of 11 patients completed follow-up. The mean Early Treatment Diabetic Retinopathy Study best corrected visual acuity was 59.9±5.7 letters (Snellen equivalent, 20/63) at baseline evaluation. The best corrected visual acuity exhibited no significant difference at month 6 compared with at baseline (57.9±6.0 letters or 20/70 at month 6; P=0.085). At month 6, mean central subfield thickness decreased from 370.4±56.5 to 334.6±65.0 μm (P=0.009). The mean amount of hard exudates increased from 4467.1±2736.1 to 6592.4±2498.3 pixels at month 6 (P=0.022). No serious adverse events occurred. CONCLUSION: Continuous intravitreal bevacizumab was found to have no benefit in visual acuity and amount of hard exudates, despite the improvement of macular edema at 6 months. |
format | Online Article Text |
id | pubmed-4136986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41369862014-08-20 Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates Jeon, Sohee Lee, Won Ki Clin Ophthalmol Original Research BACKGROUND: We evaluated the efficacy of intravitreal bevacizumab on diabetic macular edema with subfoveal and perifoveal hard exudates. MATERIALS AND METHODS: Eleven eyes (11 patients) exhibiting diabetic macular edema with subfoveal and perifoveal hard exudates were included in this prospective, nonrandomized interventional pilot study. All patients were treated with monthly scheduled intravitreal bevacizumab injections for 6 months. Changes in the Early Treatment Diabetic Retinopathy Study best corrected visual acuity, amount of hard exudates on fundus photography, and macular edema detected by central subfield thickness on spectral domain optical coherence tomography after six serial injections, were assessed. The amount of hard exudates at each visit was evaluated as pixels in fundus photography, using an Adobe Photoshop program. RESULTS: Ten of 11 patients completed follow-up. The mean Early Treatment Diabetic Retinopathy Study best corrected visual acuity was 59.9±5.7 letters (Snellen equivalent, 20/63) at baseline evaluation. The best corrected visual acuity exhibited no significant difference at month 6 compared with at baseline (57.9±6.0 letters or 20/70 at month 6; P=0.085). At month 6, mean central subfield thickness decreased from 370.4±56.5 to 334.6±65.0 μm (P=0.009). The mean amount of hard exudates increased from 4467.1±2736.1 to 6592.4±2498.3 pixels at month 6 (P=0.022). No serious adverse events occurred. CONCLUSION: Continuous intravitreal bevacizumab was found to have no benefit in visual acuity and amount of hard exudates, despite the improvement of macular edema at 6 months. Dove Medical Press 2014-08-12 /pmc/articles/PMC4136986/ /pubmed/25143708 http://dx.doi.org/10.2147/OPTH.S66405 Text en © 2014 Jeon and Lee. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Jeon, Sohee Lee, Won Ki Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates |
title | Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates |
title_full | Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates |
title_fullStr | Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates |
title_full_unstemmed | Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates |
title_short | Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates |
title_sort | effect of intravitreal bevacizumab on diabetic macular edema with hard exudates |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136986/ https://www.ncbi.nlm.nih.gov/pubmed/25143708 http://dx.doi.org/10.2147/OPTH.S66405 |
work_keys_str_mv | AT jeonsohee effectofintravitrealbevacizumabondiabeticmacularedemawithhardexudates AT leewonki effectofintravitrealbevacizumabondiabeticmacularedemawithhardexudates |